FORMULATIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA, OR ALLERGIC RHINITIS
Formulations comprising combinations of free amino acids useful for treating ARDS, asthma, or allergic rhinitis are described herein. Use of such amino acid formulations for treating ARDS, asthma, or allergic rhinitis in a subject in need thereof; in methods for treating ARDS, asthma, or allergic rhinitis in a subject in need thereof; and/or in the preparation of a medicament for the treatment of ARDS, asthma, or allergic rhinitis are encompassed herein.
1 . A pharmaceutical formulation for use in treating acute respiratory distress syndrome (ARDS), asthma, or allergic rhinitis in a subject in need thereof, wherein the formulation comprises a therapeutically effective combination of free amino acids:
the free amino acids consisting essentially of or consisting of a therapeutically effective amount of free amino acids of arginine and lysine; and
a therapeutically effective amount of at least one of free amino acids of glutamine, tryptophan, tyrosine, cysteine, asparagine, or threonine, or any combination thereof,
wherein the therapeutically effective combination of free amino acids is formulated for delivery to the lungs for treating ARDS or asthma and the therapeutically effective combination of free amino acids is sufficient to reduce fluid accumulation in the lungs of the subject; or
wherein the therapeutically effective combination of free amino acids is formulated for delivery to the nasal passages for treating allergic rhinitis and the therapeutically effective combination of free amino acids is sufficient to reduce fluid accumulation in the nasal passages of the subject; and
optionally, at least one pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, excipient, or water, or any combination thereof.
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . The pharmaceutical formulation according to claim 1 , wherein the concentration of arginine ranges from 4 mM to 10 mM; wherein the concentration of arginine ranges from 6 mM to 10 mM; wherein the concentration of arginine ranges from 7 mM to 9 mM; wherein the concentration of arginine ranges from 7.2 mM to 8.8 mM; or wherein the concentration of arginine is 8 mM.
6 . The pharmaceutical formulation according to claim 1 , wherein the therapeutically effective combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, tryptophan, tyrosine, and glutamine.
7 . The pharmaceutical formulation according to claim 6 , wherein arginine is present at a concentration ranging from 6 mM to 10 mM, lysine is present at a concentration ranging from 6 mM to 10 mM, tryptophan is present at a concentration ranging from 6 mM to 10 mM, tyrosine is present at a concentration ranging from 0.1 mM to 1.2 mM, and glutamine is present at a concentration ranging from 6 mM to 10 mM.
8 . (canceled)
9 . (canceled)
10 . The pharmaceutical formulation according to claim 1 , wherein the therapeutically effective combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, tryptophan, and glutamine.
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . The pharmaceutical formulation according to claim 1 , wherein the therapeutically effective combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, tyrosine, and glutamine.
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . The pharmaceutical formulation according to claim 1 , wherein the therapeutically effective combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, glutamine, cysteine, and asparagine.
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . The pharmaceutical formulation according to claim 1 , wherein the therapeutically effective combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, and tryptophan.
23 . The pharmaceutical formulation according to claim 1 , wherein the combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, tryptophan, threonine, and tyrosine.
24 . The pharmaceutical formulation according to claim 1 , wherein the combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, tryptophan, threonine, and glutamine.
25 . The pharmaceutical formulation according to claim 1 , wherein the therapeutically effective combination of free amino acids consists essentially of or consists of a therapeutically effective amount of free amino acids of arginine, lysine, tryptophan, tyrosine, glutamine, and threonine.
26 . The pharmaceutical formulation according to claim 1 , further comprising at least one pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, excipient, or water, or any combination thereof.
27 . The pharmaceutical formulation according to claim 1 , wherein at least one of the free amino acids or each of the free amino acids comprises L-amino acids.
28 . The pharmaceutical formulation according to claim 1 , wherein the pharmaceutical formulation is formulated for administration by a pulmonary, inhalation, or intranasal route.
29 . (canceled)
30 . The pharmaceutical formulation according to claim 1 , wherein the subject is a mammal.
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . The pharmaceutical formulation according to claim 1 , wherein the subject is afflicted with coronavirus disease 2019 (COVID-19).
35 . The pharmaceutical formulation according to claim 1 , wherein reducing fluid accumulation in the lungs reduces at least one symptom associated with ARDS or asthma and wherein reducing fluid accumulation in the nasal passages reduces at least one symptom associated with allergic rhinitis.
36 . (canceled)
37 . (canceled)
38 . A method for treating ARDS, asthma, or allergic rhinitis in a subject in need thereof, the method comprising:
administering to the subject in need thereof the pharmaceutical formulation of claim 1 ,
wherein the administering reduces fluid accumulation in the lung, thereby reducing at least one symptom associated with ARDS or asthma in the subject, or
the administering reduces fluid accumulation in the nasal passages of the subject, thereby reducing at least one symptom associated with allergic rhinitis in the subject.
39 . The method of claim 38 , wherein the pharmaceutical formulation or the medicament is administrable via at least one of a pulmonary, inhalation, or intranasal route, or any combination thereof.
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . A device comprising a pharmaceutical formulation of claim 1 , wherein the device is configured to deliver the pharmaceutical formulation or the medicament to the lungs or nasal passages of the subject in need thereof.